BioCentury | Jun 25, 2007
Finance

Ebb & Flow

...A9). The most recent prior gene therapy IPO, Ark Therapeutics (LSE:AKT), went in March 2004. ABN AMRO Rothschild...
BioCentury | Jun 23, 2007
Financial News

TopoTarget raises $64.7 million

...proposed to sell 12-15 million shares earlier this month, when its share price was DKK33.90. ABN AMRO Rothschild...
BioCentury | Jun 21, 2007
Financial News

Amsterdam Molecular prices IPO

...proposed EUR 8-EUR 10 range and values the company at EUR 139.3 million ($186.4 million). ABN AMRO Rothschild...
BioCentury | Jun 11, 2007
Finance

Ebb & Flow

...held by Advent Venture; Forbion Capital; Gilde; Essential Medical Treatments, Credit Agricole, and Amsterdam Medical. ABN AMRO Rothschild...
BioCentury | Jun 7, 2007
Financial News

Amsterdam Molecular updates IPO plans

...EUR 45 million ($60.5 million) and value the company at EUR 125.4 million ($168.6 million). ABN AMRO Rothschild...
BioCentury | May 28, 2007
Finance

Adding up Addex

...single round of venture financing, gene therapy play Amsterdam Molecular filed on Euronext Amsterdam's Eurolist. ABN AMRO Rothschild...
BioCentury | May 23, 2007
Financial News

Amsterdam Molecular planning IPO

...said it is planning an IPO on Euronext Amsterdam's Eurolist within the next few weeks. ABN AMRO Rothschild...
BioCentury | Nov 29, 2006
Financial News

TopoTarget raises $22.2 million

...CSE:TOPO) raised DKK126.7 million ($22.2 million) in a placing of 4.2 million shares at DKK30.50. ABN AMRO Rothschild...
BioCentury | Nov 28, 2006
Financial News

TopoTarget plans placing

...sold in full at TOPO's Friday close of DKK32.60, TOPO would raise DKK135.40 ($23.8 million). ABN AMRO Rothschild...
BioCentury | Jan 28, 2006
Financial News

Genmab raises $119.5 million

...shares at DKK147, which was GEN's closing price on Thursday. Merrill Lynch; Alfred Berg; and ABN AMRO Rothschild...
Items per page:
1 - 10 of 47
BioCentury | Jun 25, 2007
Finance

Ebb & Flow

...A9). The most recent prior gene therapy IPO, Ark Therapeutics (LSE:AKT), went in March 2004. ABN AMRO Rothschild...
BioCentury | Jun 23, 2007
Financial News

TopoTarget raises $64.7 million

...proposed to sell 12-15 million shares earlier this month, when its share price was DKK33.90. ABN AMRO Rothschild...
BioCentury | Jun 21, 2007
Financial News

Amsterdam Molecular prices IPO

...proposed EUR 8-EUR 10 range and values the company at EUR 139.3 million ($186.4 million). ABN AMRO Rothschild...
BioCentury | Jun 11, 2007
Finance

Ebb & Flow

...held by Advent Venture; Forbion Capital; Gilde; Essential Medical Treatments, Credit Agricole, and Amsterdam Medical. ABN AMRO Rothschild...
BioCentury | Jun 7, 2007
Financial News

Amsterdam Molecular updates IPO plans

...EUR 45 million ($60.5 million) and value the company at EUR 125.4 million ($168.6 million). ABN AMRO Rothschild...
BioCentury | May 28, 2007
Finance

Adding up Addex

...single round of venture financing, gene therapy play Amsterdam Molecular filed on Euronext Amsterdam's Eurolist. ABN AMRO Rothschild...
BioCentury | May 23, 2007
Financial News

Amsterdam Molecular planning IPO

...said it is planning an IPO on Euronext Amsterdam's Eurolist within the next few weeks. ABN AMRO Rothschild...
BioCentury | Nov 29, 2006
Financial News

TopoTarget raises $22.2 million

...CSE:TOPO) raised DKK126.7 million ($22.2 million) in a placing of 4.2 million shares at DKK30.50. ABN AMRO Rothschild...
BioCentury | Nov 28, 2006
Financial News

TopoTarget plans placing

...sold in full at TOPO's Friday close of DKK32.60, TOPO would raise DKK135.40 ($23.8 million). ABN AMRO Rothschild...
BioCentury | Jan 28, 2006
Financial News

Genmab raises $119.5 million

...shares at DKK147, which was GEN's closing price on Thursday. Merrill Lynch; Alfred Berg; and ABN AMRO Rothschild...
Items per page:
1 - 10 of 47